News
-
-
-
PRESS RELEASE
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Edesa Biotech, Inc. (Nasdaq:EDSA) reported financial results for Q1 2024 and detailed progress on clinical developments for its biopharmaceutical assets, including ARDS drug candidate EB05 and dermatitis drug candidate EB01. The company also announced future plans for key industry conferences and engagement with potential commercialization partners -
PRESS RELEASE
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
Edesa Biotech, Inc. (Nasdaq:EDSA) will be participating in the 2024 Dermatology Summit on January 7, 2024, and in one-on-one meetings alongside the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024 in San Fransico, California. Attendees interested in meeting with management can request meetings by contacting Edesa at investors@edesabiotech.com. Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases. The company is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), and has also received regulatory approval to conduct a Phase 2 trial of its EB06 monoclonal antibody as a treatment for vitiligo. Additionally, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD) and is planning a future Phase 2 study of paridiprubart for fibrotic diseases. For more information, contact Gary Koppenjan at (289) 800-9600 or investors@edesabiotech.com. -
PRESS RELEASE
Edesa Biotech Reports Fiscal Year 2023 Results
-
-
-
-
-
-
Allied Universal Event Services Professional Winner of Golden State Warriors’ Champion Spotlight Annual Starting 5
-
Viking Capital Announces Closing of Latest 252 Unit Acquisition in Austin - San Antonio Corridor
-
Assays Confirm High-Grade Tarcoola Open Pit Extensions
-
Seismic Survey Reveals Tarcoola Goldfield Architecture
-
OTCQB Trading Secured with DTCC Registration Approval
-
Turkiye Garanti Bankasi A.S.: Prospectus – Summary
-
Turkiye Garanti Bankasi A.S.: Prospectus – Capital Markets Instrument Note
-
EQS-Adhoc: United Internet AG: Non-scheduled, non-cash impairment on Tele Columbus investment
-
Shelly Group: Successful placement of shares with participation of BIT Capital for targeted increase in free float
-
Extraordinary General Meeting of 12 June 2024 - All proposals of the Board of Directors were confirmed by the General Meeting
-
Monthly disclosure of the total number of shares and voting rights - 31/05/2024
-
Combined General Meeting, June 13, 2024
-
Europorte and Kerlink revolutionize freight by launching Track Value, the first logistics application using Kinéis IoT space connectivity
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2024
-
Declaration of voting rights at the end of May 2024